Should it matter where a new medicine was first discovered? John Stanford examines how global biotech partnerships can support American drug development, and why restricting them may have consequences for patients. #Biotech #Innovation #Biotechnology @johnbstanford @MedicineMa80739 @incub8coalition @SMMT_TX

“And we’re behind.” Eddie Pauline discusses China’s expanding biotech investment and clinical trial capabilities, and the opportunity to strengthen U.S. biotechnology through research hubs like Ohio. youtu.be/1K9tZSpMVwI?si=N0xE… via @YouTube #biotech #innovation #shorts @johnbstanford @incub8coalition @OSUWexMed @ClevelandClinic @JobsOhio @MedicineMa80739

Can AI Really Deliver 100 Years of Biotech Progress in 10? #biotech #inn... youtu.be/nYYle-5Ng8Q?si=muic… via @YouTube “100 years of biotech in the next 10 years.” It's a powerful prediction about AI. Thomas Kaiser does the math, and argues that fulfilling it would require roughly 450–550 new drugs per year. Transformative technology? Absolutely. But extraordinary claims still need numbers behind them. #AI #Biotech #DrugDiscovery @johnbstanford @incub8coalition @FDA @NIH @DCVCBio @DCVC @AvicennaAi @MedicineMa80739

“Good Ideas Are Cheap”: The Reality of AI Drug Discovery #shorts #biotec... youtu.be/ngcdVgkjBWI?si=cTD2… via @YouTube “Good ideas are cheap. Durable ideas are the hard part.” That's Thomas Kaiser's reality check for AI in drug discovery. AI can dramatically expand what scientists can explore. But generating more ideas isn't the same as producing more successful medicines. #AIDrugDiscovery #Biotech #AI @incub8coalition @johnbstanford @FDA @NIH @AvicennaAi @DCVCBio @DCVC @MedicineMa80739

11 Compounds. 2 Drug Candidates. Is This AI’s Biotech Breakthrough? #sho... youtu.be/_VJ5-XjV42A?si=UX2N… via @YouTube Full Episode out NOW! #AIDrugDiscovery #Biotech #DrugDiscovery @incub8coalition @johnbstanford @DCVCBio @DCVC @MedicineMa80739

$12 billion. That's roughly a quarter of the venture capital invested in life sciences in 2025, committed to a single biotech acquisition. John Stanford explains what the Novartis/Avidity story reveals about the extraordinary risk behind drug development. Watch the full episode on YouTube @MakingMedicinePod #Biotech #Pharma #DrugDevelopment #LifeSciences

The cost of opening a Phase 1 clinical trial in the U.S. has doubled since 2017. Companies are opening fewer trials here and moving more research overseas. The bigger question: Could American patients stop being first in line for new breakthroughs? #ClinicalTrials #Biotech #DrugDevelopment Watch the full episode on YouTube @MakingMedicinePod